Sanofi-aventis acquires Merck's interest in Merial Ltd.
Whitehouse Station, N.J. -- Global pharmaceutical company Sanofi-aventis is now sole owner of Merial Ltd. after purchasing Merck & Co.?s remaining 50 percent interest for $4 billion.
Whitehouse Station, N.J.
-- Global pharmaceutical company Sanofi-aventis is now sole owner of Merial Ltd. after purchasing Merck & Co.'s remaining 50 percent interest for $4 billion.
Richard Clark, Sanofi-aventis president and CEO, said the deal allows the ongoing merger between Merck and Intervet/Schering-Plough Animal Health to stay on track.
If Merck and Shering-Plough merge, Sanofi-aventis has the option to combine Merial with the newly merged company under a joint venture. Such a deal would still be subject to approval by international antitrust authorities.
UN, WHO address public health concern over avian flu transmission to humans
April 18th 2024Veterinary professionals working with certain animals are advised to take precautionary steps to minimize risk of infection, while researchers in Texas study potential H5N1 vaccines, antivirals, and antibody therapies for humans
Read More
